On October 23, 2023, the board of directors of Procaps Group, S.A. appointed Sandra Sanchez y Oldenhage as a director to fill the vacancy on the Board created by Alejandro Weinstein?s previous resignation, effective immediately for a period ending at the annual general meeting of shareholders approving the annual accounts for the fiscal year ended December 31, 2023 (which corresponds to the duration of mandate of Mr. Weinstein). The Board determined that Ms. Sanchez y Oldenhage meets the definition of an independent director for purposes of serving on the Board under applicable Nasdaq Stock Market rules. Sandra Sanchez y Oldenhage has over 35 years?

experience in steering mature, start-up, and turn-around/restructuring enterprises toward tangible, sustainable growth within diverse international markets. She currently serves as president and chief executive officer of PharmAdvice, a consulting firm offering pharmaceutical, medical device and biotech guidance to healthcare companies entering or operating in Mexico. Previously, she oversaw oncology operations for the North LatAm region at Novartis during 2019 and 2020.

She also currently serves as a director on the board of directors of Fenix Holding and Farmapiel, specifically holding the title of chair of the nominations, compensation, and governance committee at Fenix Holding, in addition to serving as a regional board member of Grupo Financiero Banorte. Moreover, she is the former chair of the Pharma Industry Trade Association (AMIIF) in Mexico. Ms. Sanchez y Oldenhage previously worked at several of the world?s leading pharmaceutical companies, including as president of Biogen?s Mexico affiliate, general manager, and country president for Amgen Inc., and as CEO of Probiomed.

She received a bachelor?s degree in business administration at Universidad Intercontinental in Mexico City, Mexico.